Suppr超能文献

吡嗪酰胺 - 对氨基苯甲酸(1/1)共晶体及转酰胺反应产物4 -(吡嗪 - 2 - 甲酰胺基)苯甲酸在熔融态下的晶体结构。

Crystal structures of the pyrazinamide-p-aminobenzoic acid (1/1) cocrystal and the transamidation reaction product 4-(pyrazine-2-carboxamido)benzoic acid in the molten state.

作者信息

Thorat Shridhar H, Sahu Sanjay Kumar, Gonnade Rajesh G

机构信息

Center for Materials Characterization, CSIR-National Chemical Laboratory, Pune 411 008, India.

出版信息

Acta Crystallogr C Struct Chem. 2015 Nov;71(Pt 11):1010-6. doi: 10.1107/S2053229615019828. Epub 2015 Oct 26.

Abstract

The synthesis of pharmaceutical cocrystals is a strategy to enhance the performance of active pharmaceutical ingredients (APIs) without affecting their therapeutic efficiency. The 1:1 pharmaceutical cocrystal of the antituberculosis drug pyrazinamide (PZA) and the cocrystal former p-aminobenzoic acid (p-ABA), C7H7NO2·C5H5N3O, (1), was synthesized successfully and characterized by relevant solid-state characterization methods. The cocrystal crystallizes in the monoclinic space group P2₁/n containing one molecule of each component. Both molecules associate via intermolecular O-H···O and N-H···O hydrogen bonds [O···O = 2.6102 (15) Å and O-H···O = 168.3 (19)°; N···O = 2.9259 (18) Å and N-H···O = 167.7 (16)°] to generate a dimeric acid-amide synthon. Neighbouring dimers are linked centrosymmetrically through N-H···O interactions [N···O = 3.1201 (18) Å and N-H···O = 136.9 (14)°] to form a tetrameric assembly supplemented by C-H···N interactions [C···N = 3.5277 (19) Å and C-H···N = 147°]. Linking of these tetrameric assemblies through N-H···O [N···O = 3.3026 (19) Å and N-H···O = 143.1 (17)°], N-H···N [N···N = 3.221 (2) Å and N-H···N = 177.9 (17)°] and C-H···O [C···O = 3.5354 (18) Å and C-H···O = 152°] interactions creates the two-dimensional packing. Recrystallization of the cocrystals from the molten state revealed the formation of 4-(pyrazine-2-carboxamido)benzoic acid, C12H9N3O3, (2), through a transamidation reaction between PZA and p-ABA. Carboxamide (2) crystallizes in the triclinic space group P1̅ with one molecule in the asymmetric unit. Molecules of (2) form a centrosymmetric dimeric homosynthon through an acid-acid O-H···O hydrogen bond [O···O = 2.666 (3) Å and O-H···O = 178 (4)°]. Neighbouring assemblies are connected centrosymmetrically via a C-H···N interaction [C···N = 3.365 (3) Å and C-H···N = 142°] engaging the pyrazine groups to generate a linear chain. Adjacent chains are connected loosely via C-H···O interactions [C···O = 3.212 (3) Å and C-H···O = 149°] to generate a two-dimensional sheet structure. Closely associated two-dimensional sheets in both compounds are stacked via aromatic π-stacking interactions engaging the pyrazine and benzene rings to create a three-dimensional multi-stack structure.

摘要

药物共晶体的合成是一种在不影响其治疗效果的情况下提高活性药物成分(API)性能的策略。成功合成了抗结核药物吡嗪酰胺(PZA)与共晶体形成剂对氨基苯甲酸(p - ABA)的1:1药物共晶体C7H7NO2·C5H5N3O,(1),并通过相关的固态表征方法对其进行了表征。该共晶体在单斜空间群P2₁/n中结晶,每个组分包含一个分子。两个分子通过分子间的O - H···O和N - H···O氢键相互缔合[O···O = 2.6102 (15) Å,O - H···O = 168.3 (19)°;N···O = 2.9259 (18) Å,N - H···O = 167.7 (16)°],生成一个二聚酸 - 酰胺合成子。相邻的二聚体通过N - H···O相互作用[N···O = 3.1201 (18) Å,N - H···O = 136.9 (14)°]中心对称连接,形成一个由C - H···N相互作用[C···N = 3.5277 (19) Å,C - H···N = 147°]补充的四聚体组装体。通过N - H···O [N···O = 3.3026 (19) Å,N - H···O = 143.1 (17)°]、N - H···N [N···N = 3.221 (2) Å,N - H···N = 177.9 (17)°]和C - H···O [C···O = 3.5354 (18) Å,C - H···O = 152°]相互作用将这些四聚体组装体连接起来,形成二维堆积。共晶体从熔融态重结晶显示通过PZA和p - ABA之间的转酰胺反应形成了4 -(吡嗪 - 2 - 甲酰胺基)苯甲酸,C12H9N3O3,(2)。羧酰胺(2)在三斜空间群P1̅中结晶,不对称单元中有一个分子。(2)的分子通过酸 - 酸O - H···O氢键[O···O = 2.666 (3) Å,O - H···O = 178 (4)°]形成一个中心对称的二聚同合成子。相邻的组装体通过与吡嗪基团相关的C - H···N相互作用[C···N = 3.365 (3) Å,C - H···N = 142°]中心对称连接,生成一条线性链。相邻的链通过C - H···O相互作用[C···O = 3.212 (3) Å,C - H···O = 149°]松散连接,生成二维片状结构。两种化合物中紧密相连的二维片层通过涉及吡嗪环和苯环的芳香π - 堆积相互作用堆叠,形成三维多堆叠结构。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验